This effect is mediated by HSCs-derived cytokines such as CCL3 (MIP-1α) that facilitates the subsequent recruitment of activated tumor-specific T cells causing enhanced anti-glioma immune response (Flores et al., 2015; Bryukhovetskiy et al., 2016). Here, CCL3 is linked to central nervous system cancer.